This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Percutaneous Removal and Margin Ablation for Breast Cancer

This study has been completed.
Department of Health and Human Services
Ethicon Endo-Surgery
RITA Medical Systems
Information provided by (Responsible Party):
University of Arkansas Identifier:
First received: December 14, 2007
Last updated: July 24, 2013
Last verified: July 2013
We hypothesize that radiofrequency ablation after single-insertion image guided vacuum assisted biopsy (IVEB) can be used to achieve negative margins in small unicentric breast cancers (≤1.5 cm).

Condition Intervention Phase
Breast Cancer Procedure: Percutaneous Removal and Margin Ablation Phase 1 Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Percutaneous Removal and Margin Ablation for Breast Cancer

Resource links provided by NLM:

Further study details as provided by University of Arkansas:

Primary Outcome Measures:
  • To quantify the degree of tumor-free margin achieved with image-guided vacuum assisted biopsy followed by ablation with radiofrequency ablation [ Time Frame: Post-surgical pathology review ]

Secondary Outcome Measures:
  • The proportion of patients with viable tumor cells beyond the margin [ Time Frame: Post-surgical pathology review ]

Enrollment: 32
Study Start Date: March 2002
Study Completion Date: October 2011
Primary Completion Date: October 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Procedure: Percutaneous Removal and Margin Ablation
Patients with a diagnosis of unicentric invasive breast cancer diagnosed by IVEB will then be assigned to the next available surgery date. On that day, the patient's axillary staging will be done, followed by ablation of the biopsy cavity using RFA. The breast surgery may include lumpectomy (which will be directed with US-guidance to assure more accurate removal of the en bloc IVEB site and the margin zone of ablation) or simple mastectomy with or without reconstruction. The tissue specimen will be sent immediately from the operating room to Pathology for routine processing.
Other Names:
  • Mammotome Breast Biopsy System (IVEB), Ethicon Endo-Surgery
  • Radiofrequency Ablation (RFA), RITA Medical Systems
  • Lumpectomy
  • Mastectomy

Detailed Description:
Using the Mammotome Breast Biopsy System (IVEB) in conjunction with MRI to predict extent of disease, ultrasound to direct removal of the tumor, touch preparation cytology for diagnosis, and ablation of margins using radiofrequency ablation (RFA), we propose to develop a comprehensive system for same-day diagnosis and treatment of patients with small breast lesions.

Ages Eligible for Study:   18 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Female, 18 to 90 years of age
  • Non-pregnant, not breastfeeding
  • Pre-study documentation of:
  • Size ≤1.5 cm cancer successfully removed by US-guided IVEB within 30 days of registration
  • Uni-centricity, unilateral cancer by radiology (mammogram and MRI)
  • Location of abnormality > 1 cm from the skin
  • Ductal Carcinoma, Invasive (Grade I-III) or In-Situ
  • No palpable axillary or supraclavicular lymph nodes
  • Good general health
  • Zubrod Performance Status of 0, 1, or 2
  • If prior non-breast malignancy, must have 5 year disease-free survival
  • No prior chemotherapy
  • Hormonal therapy must be stopped
  • Therapy with tamoxifen must have been of 14 days or less duration

Exclusion Criteria:

  • Subjects less than 18 years of age or greater than 90 years of age
  • Pregnant or breastfeeding
  • Male
  • Prior Breast Biopsy affected breast
  • Breast implants
  • Multicentric disease, bilateral disease
  • Residual disease after IVEB of > 1cm on MRI
  • Lesions > 1.5 cm in diameter
  • Lesions < 1 cm from skin surface
  • Previous radiation therapy to the breast
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00574301

United States, Arkansas
University of Arkansas For Medical Sciences
Little Rock, Arkansas, United States, 72205
Sponsors and Collaborators
University of Arkansas
Department of Health and Human Services
Ethicon Endo-Surgery
RITA Medical Systems
Principal Investigator: V. Suzanne Klimberg, MD University of Arkansas
  More Information

Responsible Party: University of Arkansas Identifier: NCT00574301     History of Changes
Other Study ID Numbers: UAMS 07050
NIH Grant 5 R21 CA097715-01
Study First Received: December 14, 2007
Last Updated: July 24, 2013

Keywords provided by University of Arkansas:
Image Guided Vacuum Assisted Biopsy
Radiofrequency Ablation
Breast Conservation Therapy

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases processed this record on September 21, 2017